Mode
Text Size
Log in / Sign up

Benzodiazepines, Dexmedetomidine, and Physical Restraints Associated with Next-Day Delirium in Critically Ill ChildrenStudy finds link between certain medications, restraints, and delirium in critically ill children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider associations between benzodiazepines, dexmedetomidine, restraints, and delirium risk in PICU children.

This secondary analysis of a pilot randomized controlled trial dataset examined 1,006 critically ill children across seven pediatric intensive care units, comprising 10,644 patient-days. The study assessed the association between previous-day administration of benzodiazepines (midazolam equivalents), opioids, and dexmedetomidine, as well as same-day physical restraint use, with the odds of delirium on a given day. No comparator group was reported for this observational analysis.

For each milligram per kilogram of midazolam equivalent administered the previous day, the adjusted odds ratio (aOR) for next-day delirium was 1.12 (95% CI, 1.02-1.25; p=0.020). Administration of dexmedetomidine on the previous day was associated with an aOR of 1.26 for next-day delirium (95% CI, 1.04-1.52; p=0.019). Same-day physical restraint use was associated with an aOR of 1.72 for delirium (95% CI, 1.27-2.31; p<0.001). Previous-day opioid administration showed no association with next-day delirium (aOR 1.00; 95% CI, 1.00-1.00; p=0.892). The study reported that no safe benzodiazepine threshold was identified, with the greatest increase in delirium odds occurring at the lowest doses (0 to 0.01 mg/kg).

Safety and tolerability data were not reported. The authors note the study did not identify a safe benzodiazepine threshold. Key limitations include the observational nature of the analysis from a secondary dataset, which precludes causal inference. Follow-up duration and funding/conflict details were not reported.

For practice, the analysis suggests associations that warrant consideration but cannot establish causation. The authors recommend minimizing benzodiazepine use when possible and employing a tailored, judicious approach to physical restraints and dexmedetomidine. Clinicians should interpret these findings within the context of the study's design limitations.

Researchers looked back at data from a previous study involving 1,006 critically ill children across seven pediatric intensive care units (PICUs). They wanted to see if certain medications or the use of physical restraints were linked to a higher chance of a child developing delirium, a state of serious confusion, the next day. They found that higher doses of benzodiazepines (like midazolam), any use of dexmedetomidine, and the use of physical restraints were each associated with increased odds of next-day delirium. Opioid pain medications were not linked to higher delirium odds in this analysis.

No safety issues or side effects from the medications were reported in this specific analysis. The main reason to be careful with these results is that this was a secondary look at old data. The study can show that these things often happened together, but it cannot prove that the medications or restraints actually caused the delirium. Other factors related to how sick the children were could explain the link.

This research suggests that doctors should be aware of these potential links when caring for very sick children. The findings support current medical advice to use these medications and restraints carefully and only when truly needed. For parents, this study highlights why medical teams work hard to manage pain and anxiety while trying to avoid confusion in their child.

What this means for you:
In critically ill kids, certain sedatives and restraints were linked to delirium risk, but this study doesn't prove they cause it.

Study Details

Study typeRct
Sample sizen = 1,006
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
IMPORTANCE: A better understanding of the relationship between sedative dose and PICU delirium is crucial for delirium prevention. OBJECTIVES: To identify risk factors for delirium in critically ill children and characterize the dose-response relationship between benzodiazepine administration and next-day delirium in the PICU. DESIGN, SETTING, AND PARTICIPANTS: A secondary analysis of 10,644 patient-days from prospectively collected data, including sedative and analgesic use and delirium screening from the multicenter, randomized PICU Up! pilot trial, including seven PICUs and 1,006 patients. MAIN OUTCOMES AND MEASURES: Delirium odds were evaluated using a multivariable logistic regression model adjusted for known delirium risk factors. RESULTS: Benzodiazepines, opioids, and dexmedetomidine were commonly used in the PICU. A higher previous-day benzodiazepine dose was associated with increased odds of delirium on a given day with an adjusted odds ratio (aOR) of 1.12 per midazolam milligram equivalent per kilogram (95% CI, 1.02-1.25; p = 0.020). The most pronounced increase in delirium risk occurred at the lowest doses, between 0 and 0.01 mg/kg (p = 0.010), with risk continuing to rise at higher doses. Previous-day opioid dose was not associated with changes in the odds of delirium (aOR, 1.00; 95% CI, 1.00-1.00; p = 0.892). Any previous-day dexmedetomidine administration was associated with increased odds of next-day delirium (aOR, 1.26; 95% CI, 1.04-1.52; p = 0.019). Additionally, same-day physical restraint use was associated with increased odds of delirium (aOR, 1.72; 95% CI, 1.27-2.31; p < 0.001). CONCLUSIONS AND RELEVANCE: No safe benzodiazepine threshold was identified in critically ill children, with delirium risk increased even at minimal doses. The greatest increase in odds occurred at the lowest doses. Hence, regardless of dose, benzodiazepine use should be minimized or eliminated whenever possible. Physical restraints and dexmedetomidine use were also associated with increased risk of delirium; thus, a tailored approach for each patient with an emphasis on judicious use is critical.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.